Out of curiosity, what business model were they trying? A few years back we were looking into virtual trial site companies (e.g. Science 37), and the pitch seemed to make sense at the time (focus on studies which require minimal site visits, use telemedicine for routine visits, coordinate with local labs and pharmacies as needed). That structure might be a good fit for rare patient cohorts.